Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab Concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas

NCT03548428 is registered in ClinicalTrials.gov with Centre Antoine Lacassagne as lead sponsor.

NCT NCT03548428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03548428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab Concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas
Lead sponsor
Centre Antoine Lacassagne
Phase
Phase 2
Overall status
Recruiting
Start date
June 4, 2020
Completion date
February 4, 2031
Enrollment
103 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

radiosurgery, sarcoma